D r . V . S . S W A T H I
A S S I S T A N T P R O F E S S O R
Viral Hepatitis
Definition
 Viral hepatitis is an inflammation that causes
liver inflammation and damage by hepatitis
virus A, B, C, D and E.
Epidemiology
 Globally around 2.3 billion people of the world
are infected with one or more of the hepatitis
virus and results around 1.4 million deaths
In India:
 Chronic HBV infection accounts for 40-50% of
hepatocellular carcinoma
 Chronic HBV infection accounts for 20-30% of
cirrhosis
 Chronic HCV infection accounts for 12-32% of
hepatocellular carcinoma
 Chronic HCV infection accounts for 12-20% of
cirrhosis
Types
 Hepatitis A- It is caused by Hepatitis A Virus (HAV), self
limiting, and leads to acute infection and mainly transmitted by
contaminated food and water
 Hepatitis B- It is caused by Hepatitis B Virus (HBV), severe, and
leads to chronic infection and mainly transmitted by injectables
 Hepatitis C- It is caused by Hepatitis C Virus (HCV), severe, and
leads to chronic infection, mainly transmitted by injectables
 Hepatitis D- It is caused by Hepatitis D Virus (HDV), commonly
occurs in patients with Hepatitis B, causes chronic infection and
mainly transmitted by injectables
 Hepatitis E- It is caused by Hepatitis E Virus (HEV), self
limiting, and causes acute infection and mainly transmitted by
contaminated food and water
Risk factors
Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E
 Poor sanitation
 Lack of safe water
 Living in a
household with
an infected
person
 Sex with hepatitis
affected partner
 Use of
recreational
drugs
 Patients
undergoing blood
transfusion and
dialysis
 Infants
 Children
 Injectable
drug users
 Patients
undergoing
blood
transfusion
and dialysis
 Injectable drug
users
 Intranasal drug
users
 Patients
undergoing blood
transfusion and
dialysis
 People live in
closed settings
 Sex with hepatitis
affected partner
 Children born to
mother infected
with HCV
 People who have
tattoos/ piercings
 Injectable
drug users
 Chronic
HBV
carriers
 People
who are
not
immune to
HBV
vaccine
 Sex with
hepatitis
affected
partner
 Poor
sanitation
 Ingestion of
undercooked
meat
 Injectable drug
users
 Patients
undergoing
blood
transfusion
and dialysis
 Children born
to mother
infected with
hepatitis
Etiology
 Hepatitis A- It is caused by Hepatitis A Virus
(HAV)
 Hepatitis B- It is caused by Hepatitis B Virus
(HBV)
 Hepatitis C- It is caused by Hepatitis C Virus
(HCV)
 Hepatitis D- It is caused by Hepatitis D Virus
(HDV)
 Hepatitis E- It is caused by Hepatitis E Virus
(HEV)
Pathogenesisof
HepatitisAandE
Pathogenesisof
HepatitisB,CandD
Continue.....
Clinical Presentation
Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E
Acute failure
 Anorexia
 Nausea
 Fatigue
 Malaise
 Vomiting
 Fever
 Head ache
 Right upper
quadrant
abdominal
pain
 Dark
urination
 Alcoholic
stools
 Pruritis
Chronic failure
 Fatigue
 Anxiety
 Anorexia
 Malaise
 Ascites
 Jaundice
 Variceal
bleeding
 Hyper
excitability
 Impaired
mentation
 Confusion
 Obtundation
 Coma
Chronic failure
 Fatigue
 Anxiety
 Anorexia
 Malaise
 Ascites
 Jaundice
 Abdominal pain
 Dark urine
Advanced stage
 Spider nevi
 Splenomegalay
 Palmar
erythema
 Testicular
atrophy
 Caput medusae
Chronic failure
 Jaundice
 Abdominal
pain
 Vomiting
 Loss of
appetite
 Dark urine
 Fatigue
Acute failure
 Anorexia
 Mild fever
 Abdominal
pain
 Itching
 Skin rash
 Joint pain
 Jaundice
 Hepatomegaly
Spider nevi
Caput medusae
Complications
 Acute / Sub acute hepatic necrosis
 Chronic hepatitis
 Cirrhosis
 Hepatic failure
 Hepatocellular carcinoma
 Glomerulonephritis
 Cryoglobulinemia
 Hepatic encephalopathy
 Portal hypertension
 Porphyria
 HIV infection
Diagnosis
 Physical examination
 Liver function tests
 Anti HAV testing
 HBSAg testing
 Anti HCV testing
 Anti HDV testing
 Anti HEV testing
 Liver biopsy
 Ultrasound of liver
Non Pharmacological Treatment
 Hepatitis vaccination for Hepatitis A, B and E
 Immunoglobulin treatment
 Counselling about risk factors and
transmission
 Stopping of alcohol
 Stopping of smoking
 Physical exercise
 Liver transplantation
Treatment Algorithm
Hepatitis A
 Vaccination
 Immunoglobulins
 Symptomatic treatment
Hepatitis B
 Interferons
 Pegylated interferons
 Entecavir
 Tenofavir
 Adenovir
 Lamivudine
 Telbivudine
Hepatitis C
Type Without Cirrhosis With Cirrhosis
Genotype
1a and 1b
Daclatasavir+ Sofosbuvir for 12
weeks
Daclatasavir+ Sofosbuvir+ Ribavirin for 24
weeks
Simeprevir + Sofosbuvir for 12
weeks
Simeprevir + Sofosbuvir+ Ribavirin for 24
weeks
Genotype
2
Daclatasavir+ Sofosbuvir for 12
weeks
Daclatasavir+ Sofosbuvir+ Ribavirin for 24
weeks
Genotype
3
Daclatasavir+ Sofosbuvir for 12
weeks
Daclatasavir+ Sofosbuvir+ Ribavirin for 24
weeks
Daclatasavir+ Ribavirin+ PEG
interferon for 12 weeks
Daclatasavir+ Ribavirin+ PEG interferon
for 12 weeks
Hepatitis D
 PEG INF for 48 weeks
 Liver transplantation in case of fulminant
hepatitis and end stage liver disease
Hepatitis E
 Vaccination
 Symptomatic treatment
 Ribavirin in case of immunosupressed people
Drugs used in treatment of viral hepatitis
Drug Category Mode of action Dose Adverse affects
IG Immunoglobulin Produces passive
immunity
0.02ml/kg -IM  Head ache
 Erythema
 Myalgia
 Malaise
 Injection site reactions
Pegylated
interferon
Immunomodulator Enhances
activity of
phagocytic
activity of
macrophages
and cytotoxic
activity of
lymphocytes for
target cells
180mcg-SC-once
weekly for 24-48-
weeks
 Fatigue
 Headache
 Fever
 Myalgia
 Influenza like illness
Entecavir Nucleoside reverse
transcriptase inhibitor
Inhibit viral
replication
0.5-1mg- PO-OD  Fatigue
 Head ache
 Dizziness
 Nausea
 Diarrhoea
Tenofavir Nucleoside
reverse
transcriptase
inhibitor
Inhibit viral
replication
300mg-PO-OD  Asthenia
 Diarrhoea
 Nausea
 Pain
 Anorexia
Lamivudine Nucleoside
reverse
transcriptase
inhibitor
Inhibit viral
replication
100mg-PO-OD  Diarrhoea
 Cough
 Fever
 Joint pain
 Pancreatitis
Telbivudine
Nucleoside
reverse
transcriptase
inhibitor
Inhibit viral
replication
600mg-PO-OD  Fatigue
 Headache
 Cough
 Diarrhoea
 Abdominal pain
Daclatasavir HCV NS5A
inhibitor
Inhibit viral
replication
60mg-PO-OD  Headache
 Nausea
 Fatigue
 Diarrhoea
 Elevation of lipase
levels
Sofosbuvir HCV NS5B
inhibitor
Inhibit viral
replication
400mg-PO-OD  Fatigue
 Headache
 Nausea
 Fatigue
 Insomnia
Simeprevir HCV protease
inhibitor
Inhibit viral
replication
150mg-PO-OD  Photosensitivity
 Hyperbilirubenemia
 Pruritis
 Dyspnoea
 Myalgia
Ribavirin Synthetic nucleoside
analog of
ribofuranose
Inhibit viral
protein synthesis
800-1000mg/day-BD  Fatigue
 Headache
 Myalgia
 Haemolysis
 Rigors
Resources
 https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC6418070/
 http://www.ijmm.org/article.asp?issn=0255-
0857;year=2018;volume=36;issue=2;spage=2
17;epage=223;aulast=Sarkar
 https://www.ncbi.nlm.nih.gov/pubmed/2979
8951
 https://doi.org/10.1111/jvh.12870
 https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC5719604/

Viral hepatitis

  • 1.
    D r .V . S . S W A T H I A S S I S T A N T P R O F E S S O R Viral Hepatitis
  • 2.
    Definition  Viral hepatitisis an inflammation that causes liver inflammation and damage by hepatitis virus A, B, C, D and E.
  • 3.
    Epidemiology  Globally around2.3 billion people of the world are infected with one or more of the hepatitis virus and results around 1.4 million deaths In India:  Chronic HBV infection accounts for 40-50% of hepatocellular carcinoma  Chronic HBV infection accounts for 20-30% of cirrhosis  Chronic HCV infection accounts for 12-32% of hepatocellular carcinoma  Chronic HCV infection accounts for 12-20% of cirrhosis
  • 4.
    Types  Hepatitis A-It is caused by Hepatitis A Virus (HAV), self limiting, and leads to acute infection and mainly transmitted by contaminated food and water  Hepatitis B- It is caused by Hepatitis B Virus (HBV), severe, and leads to chronic infection and mainly transmitted by injectables  Hepatitis C- It is caused by Hepatitis C Virus (HCV), severe, and leads to chronic infection, mainly transmitted by injectables  Hepatitis D- It is caused by Hepatitis D Virus (HDV), commonly occurs in patients with Hepatitis B, causes chronic infection and mainly transmitted by injectables  Hepatitis E- It is caused by Hepatitis E Virus (HEV), self limiting, and causes acute infection and mainly transmitted by contaminated food and water
  • 5.
    Risk factors Hepatitis AHepatitis B Hepatitis C Hepatitis D Hepatitis E  Poor sanitation  Lack of safe water  Living in a household with an infected person  Sex with hepatitis affected partner  Use of recreational drugs  Patients undergoing blood transfusion and dialysis  Infants  Children  Injectable drug users  Patients undergoing blood transfusion and dialysis  Injectable drug users  Intranasal drug users  Patients undergoing blood transfusion and dialysis  People live in closed settings  Sex with hepatitis affected partner  Children born to mother infected with HCV  People who have tattoos/ piercings  Injectable drug users  Chronic HBV carriers  People who are not immune to HBV vaccine  Sex with hepatitis affected partner  Poor sanitation  Ingestion of undercooked meat  Injectable drug users  Patients undergoing blood transfusion and dialysis  Children born to mother infected with hepatitis
  • 6.
    Etiology  Hepatitis A-It is caused by Hepatitis A Virus (HAV)  Hepatitis B- It is caused by Hepatitis B Virus (HBV)  Hepatitis C- It is caused by Hepatitis C Virus (HCV)  Hepatitis D- It is caused by Hepatitis D Virus (HDV)  Hepatitis E- It is caused by Hepatitis E Virus (HEV)
  • 7.
  • 8.
  • 9.
  • 10.
    Clinical Presentation Hepatitis AHepatitis B Hepatitis C Hepatitis D Hepatitis E Acute failure  Anorexia  Nausea  Fatigue  Malaise  Vomiting  Fever  Head ache  Right upper quadrant abdominal pain  Dark urination  Alcoholic stools  Pruritis Chronic failure  Fatigue  Anxiety  Anorexia  Malaise  Ascites  Jaundice  Variceal bleeding  Hyper excitability  Impaired mentation  Confusion  Obtundation  Coma Chronic failure  Fatigue  Anxiety  Anorexia  Malaise  Ascites  Jaundice  Abdominal pain  Dark urine Advanced stage  Spider nevi  Splenomegalay  Palmar erythema  Testicular atrophy  Caput medusae Chronic failure  Jaundice  Abdominal pain  Vomiting  Loss of appetite  Dark urine  Fatigue Acute failure  Anorexia  Mild fever  Abdominal pain  Itching  Skin rash  Joint pain  Jaundice  Hepatomegaly
  • 11.
  • 12.
  • 13.
    Complications  Acute /Sub acute hepatic necrosis  Chronic hepatitis  Cirrhosis  Hepatic failure  Hepatocellular carcinoma  Glomerulonephritis  Cryoglobulinemia  Hepatic encephalopathy  Portal hypertension  Porphyria  HIV infection
  • 14.
    Diagnosis  Physical examination Liver function tests  Anti HAV testing  HBSAg testing  Anti HCV testing  Anti HDV testing  Anti HEV testing  Liver biopsy  Ultrasound of liver
  • 16.
    Non Pharmacological Treatment Hepatitis vaccination for Hepatitis A, B and E  Immunoglobulin treatment  Counselling about risk factors and transmission  Stopping of alcohol  Stopping of smoking  Physical exercise  Liver transplantation
  • 18.
    Treatment Algorithm Hepatitis A Vaccination  Immunoglobulins  Symptomatic treatment Hepatitis B  Interferons  Pegylated interferons  Entecavir  Tenofavir  Adenovir  Lamivudine  Telbivudine
  • 19.
    Hepatitis C Type WithoutCirrhosis With Cirrhosis Genotype 1a and 1b Daclatasavir+ Sofosbuvir for 12 weeks Daclatasavir+ Sofosbuvir+ Ribavirin for 24 weeks Simeprevir + Sofosbuvir for 12 weeks Simeprevir + Sofosbuvir+ Ribavirin for 24 weeks Genotype 2 Daclatasavir+ Sofosbuvir for 12 weeks Daclatasavir+ Sofosbuvir+ Ribavirin for 24 weeks Genotype 3 Daclatasavir+ Sofosbuvir for 12 weeks Daclatasavir+ Sofosbuvir+ Ribavirin for 24 weeks Daclatasavir+ Ribavirin+ PEG interferon for 12 weeks Daclatasavir+ Ribavirin+ PEG interferon for 12 weeks
  • 20.
    Hepatitis D  PEGINF for 48 weeks  Liver transplantation in case of fulminant hepatitis and end stage liver disease Hepatitis E  Vaccination  Symptomatic treatment  Ribavirin in case of immunosupressed people
  • 21.
    Drugs used intreatment of viral hepatitis Drug Category Mode of action Dose Adverse affects IG Immunoglobulin Produces passive immunity 0.02ml/kg -IM  Head ache  Erythema  Myalgia  Malaise  Injection site reactions Pegylated interferon Immunomodulator Enhances activity of phagocytic activity of macrophages and cytotoxic activity of lymphocytes for target cells 180mcg-SC-once weekly for 24-48- weeks  Fatigue  Headache  Fever  Myalgia  Influenza like illness Entecavir Nucleoside reverse transcriptase inhibitor Inhibit viral replication 0.5-1mg- PO-OD  Fatigue  Head ache  Dizziness  Nausea  Diarrhoea
  • 22.
    Tenofavir Nucleoside reverse transcriptase inhibitor Inhibit viral replication 300mg-PO-OD Asthenia  Diarrhoea  Nausea  Pain  Anorexia Lamivudine Nucleoside reverse transcriptase inhibitor Inhibit viral replication 100mg-PO-OD  Diarrhoea  Cough  Fever  Joint pain  Pancreatitis Telbivudine Nucleoside reverse transcriptase inhibitor Inhibit viral replication 600mg-PO-OD  Fatigue  Headache  Cough  Diarrhoea  Abdominal pain
  • 23.
    Daclatasavir HCV NS5A inhibitor Inhibitviral replication 60mg-PO-OD  Headache  Nausea  Fatigue  Diarrhoea  Elevation of lipase levels Sofosbuvir HCV NS5B inhibitor Inhibit viral replication 400mg-PO-OD  Fatigue  Headache  Nausea  Fatigue  Insomnia Simeprevir HCV protease inhibitor Inhibit viral replication 150mg-PO-OD  Photosensitivity  Hyperbilirubenemia  Pruritis  Dyspnoea  Myalgia Ribavirin Synthetic nucleoside analog of ribofuranose Inhibit viral protein synthesis 800-1000mg/day-BD  Fatigue  Headache  Myalgia  Haemolysis  Rigors
  • 24.
    Resources  https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC6418070/  http://www.ijmm.org/article.asp?issn=0255- 0857;year=2018;volume=36;issue=2;spage=2 17;epage=223;aulast=Sarkar https://www.ncbi.nlm.nih.gov/pubmed/2979 8951  https://doi.org/10.1111/jvh.12870  https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC5719604/